

130  
134. (New) A method according to claim 133, wherein the agent capable of providing protection from U.V. radiation is oxybenzone.

131  
135. (New) A method according to claim 112, wherein said agent is LIPOFUNDIN™.

132  
136. (New) A method according to claim 78, wherein said agent is INTRALIPID™.--

### REMARKS

The Office Action of January 18, 2001 has been carefully considered. The Examiner's favorable Action is acknowledged with appreciation. It is again respectfully submitted that the claims presented for examination were claims 72-111, not claims 72-107 as noted in the Action.

Correction is requested inasmuch as new claims 112-136 are now being presented in lieu of cancelled claims 72-103.

Thus, the claims now in the case are claims 104-136. Examination of all these claims is respectfully urged.

The rejection of claims 72-78 under §112, first paragraph, is now moot by virtue of cancellation of claim 72. As for claim 105 (and also claims 135,136), the use of trademarks in claims is permitted when the product to which the trade refers has a known identify and is capitalized (MPEP §608.01(v)).

Here, the trademarked products LIPOFUNDIN™ and INTRALIPID™ have known compositions, namely:

<b>Ingredient</b>	<b>LIPOFUNDIN™ (10%)</b>	<b>INTRALIPID™ (10%)</b>
Soybean oil	50.0 gr	100.0 gr
Egg lecithin	12.0 gr	12.0 gr
Glycerol	25.0 gr	22.0 gr
Medium-chain Triglycerides	50.0 gr	

See enclosed product specification sheets for both LIPOFUNDIN™ and INTRALIPID™.

Should the Examiner believe it to be necessary, Applicant will amend the specification to identify the above trademarked products with greater specificity since the identity was shown at the time the application was filed.

As no art was applied against any of the claims now presented, favorable reconsideration is respectfully urged. The WO patent applied against cancelled claims 72 and 73 under §102 is respectfully traversed for the following reason.

The present invention provides a treatment which leads to the regeneration of epithelium layer in the anterior of the eye, that is to the formation of tissue which is a result of cell proliferation. In contradiction thereto, the WO reference teaches a method of inhibiting cell proliferation. Thus, not only does this publication not anticipate the method of the present invention, it in fact teaches away from the claimed invention, since it produces the opposite end effect, i.e. proliferation vs. inhibition.

Lastly, the Examiner's requested for election of a second specie is not understood. Clarification is requested.


Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned **"Version with markings to show changes made."**

Please charge any shortage or credit any overpayment of fees to BLANK ROME COMISKY & MCCAULEY LLP, *WIGMAN, COHEN, LEITNER & MYERS IP GROUP*, Deposit Account No. 23-2185 (000744.00077). In the event that a petition for an extension of time is required to be submitted herewith and in the event that a separate petition does not accompany this response, Applicants hereby petition under 37 C.F.R. §1.136(a) for an extension of time for as many months as are required to render this submission timely. Any fee due is authorized above.

Respectfully submitted,

Date: April 16, 2001

By:

  
Herbert Cohen  
Registration No. 25,109

BLANK ROME COMISKY & MCCAULEY LLP  
*WIGMAN, COHEN, LEITNER & MYERS IP GROUP*  
900 17th Street, N.W., Suite 1000  
Washington, D.C. 20006  
(202) 530-7400 (Telephone)  
(202) 463-6915 (Facsimile)

In Re: N. Savion et al. - Application Serial No. 09/341,049 filed August 9, 1999  
Examiner Z. Fay, Art Unit 1614

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the claims:**

Claims 72-103 have been cancelled.

Claim 105 has been amended as follows:

105. (Amended) A storage medium according to claim 104, wherein the agent is one or more of the group consisting of:

- iii. [Lipofundin] LIPOFUNDIN<sup>TM</sup>
- iv. [Intralipid] INTRALIPID<sup>TM</sup>